Medtronic PLC Forecasted to Earn Q2 2018 Earnings of $1.05 Per Share (MDT)
Medtronic PLC (NYSE:MDT) – Research analysts at William Blair reduced their Q2 2018 earnings per share estimates for shares of Medtronic PLC in a report released on Wednesday. William Blair analyst K. Krum now anticipates that the medical technology company will post earnings per share of $1.05 for the quarter, down from their prior forecast of $1.18. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Medtronic PLC’s Q3 2018 earnings at $1.20 EPS, Q4 2018 earnings at $1.39 EPS, FY2018 earnings at $4.77 EPS, Q1 2019 earnings at $1.12 EPS, Q2 2019 earnings at $1.22 EPS and FY2019 earnings at $5.15 EPS.
Medtronic PLC (NYSE:MDT) last posted its quarterly earnings data on Tuesday, August 22nd. The medical technology company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.04. The company had revenue of $7.39 billion for the quarter, compared to analyst estimates of $7.44 billion. Medtronic PLC had a net margin of 13.75% and a return on equity of 12.92%. Medtronic PLC’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.03 earnings per share.
Several other research analysts also recently issued reports on the stock. Goldman Sachs Group, Inc. (The) started coverage on shares of Medtronic PLC in a research report on Tuesday, May 16th. They set a “neutral” rating and a $87.00 price target on the stock. Zacks Investment Research downgraded shares of Medtronic PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, May 23rd. Evercore ISI reiterated an “outperform” rating and set a $91.00 price target (up previously from $88.50) on shares of Medtronic PLC in a research report on Sunday, May 28th. BMO Capital Markets boosted their price objective on Medtronic PLC from $87.00 to $94.00 and gave the stock an “outperform” rating in a report on Tuesday, May 30th. Finally, Morgan Stanley boosted their price objective on Medtronic PLC from $84.00 to $86.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 30th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $88.78.
Medtronic PLC (MDT) traded down 0.21% on Monday, reaching $79.42. 958,324 shares of the company’s stock were exchanged. Medtronic PLC has a 1-year low of $69.35 and a 1-year high of $89.72. The stock’s 50 day moving average price is $84.48 and its 200 day moving average price is $83.39. The firm has a market capitalization of $108.16 billion, a price-to-earnings ratio of 26.73 and a beta of 1.02.
A number of hedge funds and other institutional investors have recently bought and sold shares of MDT. Parkside Financial Bank & Trust boosted its position in Medtronic PLC by 22.4% in the second quarter. Parkside Financial Bank & Trust now owns 1,146 shares of the medical technology company’s stock valued at $102,000 after buying an additional 210 shares during the last quarter. BDO Wealth Advisors LLC purchased a new position in Medtronic PLC during the second quarter valued at $103,000. Motco boosted its position in Medtronic PLC by 8.7% in the second quarter. Motco now owns 1,239 shares of the medical technology company’s stock valued at $110,000 after buying an additional 99 shares during the last quarter. Quadrant Capital Group LLC boosted its position in Medtronic PLC by 21.5% in the second quarter. Quadrant Capital Group LLC now owns 1,639 shares of the medical technology company’s stock valued at $114,000 after buying an additional 290 shares during the last quarter. Finally, Israel Discount Bank of New York purchased a new position in Medtronic PLC during the first quarter valued at $117,000. Hedge funds and other institutional investors own 80.49% of the company’s stock.
In other Medtronic PLC news, EVP Bryan C. Hanson sold 12,000 shares of the stock in a transaction on Monday, July 17th. The stock was sold at an average price of $88.57, for a total transaction of $1,062,840.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard H. Anderson acquired 5,600 shares of the stock in a transaction on Wednesday, June 21st. The shares were purchased at an average price of $88.90 per share, for a total transaction of $497,840.00. Following the transaction, the director now directly owns 71,910 shares in the company, valued at $6,392,799. The disclosure for this purchase can be found here. 0.25% of the stock is currently owned by corporate insiders.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 29th will be paid a $0.46 dividend. This represents a $1.84 dividend on an annualized basis and a yield of 2.31%. The ex-dividend date of this dividend is Thursday, September 28th. Medtronic PLC’s dividend payout ratio (DPR) is presently 61.95%.
Medtronic PLC Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.